Nkarta (NKTX) Competitors $2.84 -0.19 (-6.27%) (As of 12:03 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NKTX vs. KURA, EOLS, RAPP, PRTA, TYRA, CRGX, AVXL, CRON, RLAY, and CGEMShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Kura Oncology (KURA), Evolus (EOLS), Rapport Therapeutics (RAPP), Prothena (PRTA), Tyra Biosciences (TYRA), CARGO Therapeutics (CRGX), Anavex Life Sciences (AVXL), Cronos Group (CRON), Relay Therapeutics (RLAY), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Kura Oncology Evolus Rapport Therapeutics Prothena Tyra Biosciences CARGO Therapeutics Anavex Life Sciences Cronos Group Relay Therapeutics Cullinan Therapeutics Kura Oncology (NASDAQ:KURA) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation. Do analysts recommend KURA or NKTX? Kura Oncology currently has a consensus price target of $29.38, suggesting a potential upside of 162.28%. Nkarta has a consensus price target of $15.00, suggesting a potential upside of 395.05%. Given Nkarta's stronger consensus rating and higher possible upside, analysts plainly believe Nkarta is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Nkarta 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more risk and volatility, KURA or NKTX? Kura Oncology has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Do institutionals & insiders hold more shares of KURA or NKTX? 80.5% of Nkarta shares are owned by institutional investors. 5.5% of Kura Oncology shares are owned by insiders. Comparatively, 8.7% of Nkarta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher earnings & valuation, KURA or NKTX? Kura Oncology is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura OncologyN/AN/A-$152.63M-$2.36-4.75NkartaN/AN/A-$117.50M-$1.88-1.61 Does the MarketBeat Community favor KURA or NKTX? Kura Oncology received 364 more outperform votes than Nkarta when rated by MarketBeat users. However, 76.92% of users gave Nkarta an outperform vote while only 69.51% of users gave Kura Oncology an outperform vote. CompanyUnderperformOutperformKura OncologyOutperform Votes42469.51% Underperform Votes18630.49% NkartaOutperform Votes6076.92% Underperform Votes1823.08% Is KURA or NKTX more profitable? Nkarta's return on equity of -27.13% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -44.09% -39.57% Nkarta N/A -27.13%-21.67% Does the media prefer KURA or NKTX? In the previous week, Kura Oncology had 1 more articles in the media than Nkarta. MarketBeat recorded 9 mentions for Kura Oncology and 8 mentions for Nkarta. Nkarta's average media sentiment score of 1.08 beat Kura Oncology's score of 0.64 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNkarta beats Kura Oncology on 12 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…Click here to reserve your free seat at the Crypto Community Summit Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$213.82M$7.05B$5.36B$8.94BDividend YieldN/A7.97%5.33%4.05%P/E Ratio-1.6111.31117.6718.00Price / SalesN/A242.101,424.20155.72Price / CashN/A62.0542.8038.60Price / Book0.5010.647.356.66Net Income-$117.50M$152.36M$118.46M$224.93M7 Day Performance16.09%3.48%3.40%2.50%1 Month Performance-5.02%-1.31%2.49%10.24%1 Year Performance11.40%31.72%36.17%30.14% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta3.9937 of 5 stars$2.84-6.3%$15.00+428.2%+11.4%$200.42MN/A-1.51140Positive NewsKURAKura Oncology4.298 of 5 stars$11.01-0.3%$29.38+166.8%+12.4%$856.14MN/A-4.68142EOLSEvolus4.2514 of 5 stars$13.46-1.7%$23.00+70.9%+38.6%$852.29M$202.09M-15.04170Positive NewsGap DownRAPPRapport Therapeutics2.4216 of 5 stars$23.13+1.3%$35.00+51.3%N/A$846.00MN/A0.00N/AShort Interest ↓Lockup ExpirationGap UpPRTAProthena1.9907 of 5 stars$15.47-4.6%$61.86+299.9%-57.0%$832.44M$91.37M-6.54173Positive NewsTYRATyra Biosciences2.7187 of 5 stars$16.05+2.4%$31.00+93.1%+36.6%$812.18MN/A-9.7420Positive NewsCRGXCARGO Therapeutics1.8452 of 5 stars$17.52-3.6%$30.33+73.1%+9.9%$806.41MN/A-4.15116AVXLAnavex Life Sciences3.7203 of 5 stars$9.40-0.6%$43.00+357.4%+23.1%$797.12MN/A-18.9240CRONCronos Group2.3149 of 5 stars$2.08flat$3.00+44.2%-1.4%$795.18M$87.24M-16.00356RLAYRelay Therapeutics3.7829 of 5 stars$4.74+0.9%$21.22+347.7%-46.3%$793.40M$10.01M-1.80304Positive NewsCGEMCullinan Therapeutics2.205 of 5 stars$13.53+0.6%$31.67+134.0%+52.1%$787.83M$18.94M-4.7430News CoveragePositive News Related Companies and Tools Related Companies Kura Oncology Competitors Evolus Competitors Rapport Therapeutics Competitors Prothena Competitors Tyra Biosciences Competitors CARGO Therapeutics Competitors Anavex Life Sciences Competitors Cronos Group Competitors Relay Therapeutics Competitors Cullinan Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NKTX) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
